<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960296</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1067</org_study_id>
    <nct_id>NCT01960296</nct_id>
  </id_info>
  <brief_title>Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?</brief_title>
  <official_title>Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who on taking clopidogrel are randomized to either continue clopidogrel into
      general surgery or discontinue clopidogrel 7 days before surgery.  All patients resume
      clopidogrel after surgery.  The investigators track the development of bleeding
      complications that may develop within 90 days of the surgery.  Patients are medically
      cleared to be in either arm of the study by their cardiologist and surgeon.  There is
      currently no evidence to support for or against the use continuation or discontinuation of
      clopidogrel prior to general surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Perioperative Bleeding Complications</measure>
    <time_frame>up to 90 days post op</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Development of perioperative bleeding complications, including need for blood transfusions, hematoma, and bleeding requiring re-admission or re-operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of myocardial infarction or thrombosis</measure>
    <time_frame>up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clopidogrel</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue home dose of clopidogrel into surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Discontinue  home dose of clopidogrel one week before surgery.  Resume after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Continue home dose of clopidogrel into surgery</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Discontinue Clopidogrel</intervention_name>
    <description>Discontinue  home dose of clopidogrel one week before surgery.  Resume after surgery.</description>
    <arm_group_label>Discontinue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  taking clopidogrel

          -  undergoing general surgery

          -  cleared by both cardiologist and surgery for randomized arm

        Exclusion Criteria:

          -  previous history of bleeding complications/bleeding disposition

          -  no capacity to consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia M Divino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malika Garg, MD</last_name>
    <phone>212-241-1982</phone>
    <email>malika.garg@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celia M Divino, MD</last_name>
    <phone>212-241-3348</phone>
    <email>celia.divino@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Chu, MD</last_name>
      <phone>407-616-7890</phone>
      <email>edward.chu@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Celia M Divino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>general surgery</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
